Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Xeno Biosciences
company
About
Xeno Biosciences is a biotechnology company that provides novel class of treatments for metabolic diseases.
- 1 - 10
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $7.25M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2015
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It was founded in 2015 and is headquartered in Somerville, Massachusetts.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$7.25M
Xeno Biosciences has raised a total of
$7.25M
in funding over 2 rounds. Their latest funding was raised on
Aug 8, 2021 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 8, 2021 | Series A | $7.25M | 4 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
4
Xeno Biosciences is funded by 4 investors.
Dirigo Angels
and Bangor Angels
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series A |
|
|
— | Series A |
|
|
— | Series A |
Keiretsu Forum
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
